Efficacy and Safety of Omalizumab in Bullous Pemphigoid
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to test the safety and efficacy of Xolair in the treatment of the
autoimmune blistering disease, bullous pemphigoid (BP).
This is a pilot, open label case-control study. Patients treated with Xolair will be compared
to patients receiving standard treatment with prednisone.
The enrollment period for the study is 24 weeks: 16 weeks active treatment and 8 additional
weeks of observation.